FY2025 EPS Forecast for Solid Biosciences Boosted by Analyst

Solid Biosciences Inc. (NASDAQ:SLDB) – Equities research analysts at Chardan Capital boosted their FY2025 earnings per share estimates for Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings of ($1.82) per share for the year, up from their prior forecast of ($2.03). Chardan Capital currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

SLDB has been the subject of several other reports. Truist Financial started coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 target price for the company. Wedbush initiated coverage on Solid Biosciences in a research report on Friday, December 13th. They issued an “outperform” rating and a $16.00 price objective for the company. JPMorgan Chase & Co. dropped their price objective on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. JMP Securities initiated coverage on shares of Solid Biosciences in a research note on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, Citizens Jmp upgraded shares of Solid Biosciences to a “strong-buy” rating in a research report on Tuesday, December 10th. Nine analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $15.40.

Solid Biosciences Price Performance

Shares of Solid Biosciences stock opened at $5.58 on Monday. The firm has a 50 day simple moving average of $3.85 and a 200 day simple moving average of $5.72. Solid Biosciences has a fifty-two week low of $2.88 and a fifty-two week high of $15.05. The firm has a market cap of $226.43 million, a P/E ratio of -1.84 and a beta of 2.01.

Insider Buying and Selling at Solid Biosciences

In related news, insider Jessie Hanrahan sold 4,610 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $25,816.00. Following the completion of the sale, the insider now owns 14,235 shares in the company, valued at $79,716. This represents a 24.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO David T. Howton sold 5,072 shares of Solid Biosciences stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $28,403.20. Following the transaction, the chief operating officer now owns 15,663 shares in the company, valued at approximately $87,712.80. This represents a 24.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,069 shares of company stock valued at $137,301. Corporate insiders own 13.63% of the company’s stock.

Hedge Funds Weigh In On Solid Biosciences

Several institutional investors and hedge funds have recently modified their holdings of SLDB. JPMorgan Chase & Co. raised its holdings in Solid Biosciences by 9,393.8% during the 4th quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company’s stock worth $3,824,000 after buying an additional 945,863 shares during the period. Redmile Group LLC acquired a new stake in shares of Solid Biosciences during the fourth quarter worth $2,461,000. Point72 Asset Management L.P. lifted its position in Solid Biosciences by 292.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 443,010 shares of the company’s stock valued at $3,088,000 after acquiring an additional 330,234 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Solid Biosciences by 270.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 264,069 shares of the company’s stock valued at $1,056,000 after acquiring an additional 192,714 shares in the last quarter. Finally, Trexquant Investment LP boosted its stake in Solid Biosciences by 256.9% in the 4th quarter. Trexquant Investment LP now owns 194,281 shares of the company’s stock worth $777,000 after purchasing an additional 139,851 shares during the period. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.